PAX5 and leukemia: WGS studies identified non‐coding recurrent mutations, including the 3′‐UTR of NOTCH1 and a PAX5 enhancer, resulting in significant activity alterations of these transcription factors genes of well‐known importance in leukemia and other malignancies (Lobry et al., 2011; O'Brien et al., 2011).